glpg-0492
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2010 (NCT01130818)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorMODULATOR
AR modulator
selective androgen modulator (SARM)
Chemistry & pharmacology
Loading structure…
SMILES
CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)[C@@]1(CO)c1ccccc1- Mol. weight
- 389.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545417 ↗
- ChEMBLCHEMBL2178100 ↗
Also known as
- 4-(4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile
- dt-200
- glpg0492
- glpg0492
- glpg0492
- glpg0492
- glpg-0492
- glpg-0492
- glpg-0492
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01538420 | Phase 1 | Jan 1, 2012 | Galapagos NV |
| NCT01397370 | Phase 1 | Jul 1, 2011 | Galapagos NV |
| NCT01130818 | Phase 1 | May 1, 2010 | Galapagos NV, SGS Life Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 3 | 3 | 1 | 2010 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1